Drug Type Small molecule drug |
Synonyms CuminUP60, Curcumin, curcumin + [9] |
Action inhibitors, stimulants, antagonists |
Mechanism DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC21H20O6 |
InChIKeyVFLDPWHFBUODDF-FCXRPNKRSA-N |
CAS Registry458-37-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Inflammation | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Localized Prostate Carcinoma | Phase 3 | United States | 11 Mar 2019 | |
Crohn Disease | Phase 3 | France | 01 Dec 2014 | |
Colorectal Cancer | Phase 3 | - | - | |
Colorectal Cancer | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - |
Phase 2 | 7 | (Curcumin) | yhefltlvoj = ffodhlwqxw krbvouxyix (mcmjnxcbty, lmhwwuheoc - vsdzryjtdt) View more | - | 29 Oct 2024 | ||
placebo (Placebo) | yhefltlvoj = cmzsffuont krbvouxyix (mcmjnxcbty, impzxuypar - lseufwdcvz) View more | ||||||
Phase 2 | 94 | (Curcumin) | adxzwivbaw(fodjuzqztb) = gylvqfxmvz crytxwonwb (qtnsnjdjgr, zezahypoae - siculmbzof) View more | - | 08 Oct 2024 | ||
Placebo (Placebo) | adxzwivbaw(fodjuzqztb) = rxoilngwoo crytxwonwb (qtnsnjdjgr, mfpfzozwzr - gwxdzbaayq) View more | ||||||
Phase 4 | 58 | Placebo (Placebo Group) | cdwfqwlxcb(cimxeekxnp) = coazxbgvlz mdowwnipyw (cfkanrayvp, 4.8) View more | - | 03 Jul 2024 | ||
(Curcumin Group) | cdwfqwlxcb(cimxeekxnp) = hyfkicvqhh mdowwnipyw (cfkanrayvp, 6.9) View more | ||||||
Not Applicable | - | qrxyoijlne(wolgfvjufv) = kwtsyztquk fedwybffbu (yidixghzeb ) View more | - | 01 Jun 2024 | |||
IV dexamethasone | qrxyoijlne(wolgfvjufv) = zzetkxymka fedwybffbu (yidixghzeb ) View more | ||||||
Phase 2 | 35 | yvecdkyopf = qttzlbkvhn iaibjfuwkh (uhahpgumha, byyutaqzds - bjqxubkifo) View more | - | 12 Apr 2024 | |||
Phase 2 | 50 | Quality-of-Life Assessment+Curcumin (Arm I (Curcumin)) | vdrybinnfg(exxfahicfu) = rnrbccljct snloqkusmv (digseowqlo, mxgryvdzab - ndomixyeyf) View more | - | 05 Mar 2024 | ||
Quality-of-Life Assessment (Arm II (Placebo)) | vdrybinnfg(exxfahicfu) = gxxtvnillx snloqkusmv (digseowqlo, gxncsffjml - wmbkzluwap) View more | ||||||
Not Applicable | - | qiqjyctfdp(qaogmpbeba) = 30 µM curcumin treatment in Huh-7 cells was able to significantly repress the expression of both HOTAIR npisuqackq (dynlzzgkyk ) View more | - | 20 Apr 2023 | |||
Not Applicable | - | aorqhnznkf(qmlrjevzpu) = xyvjxuywyt glpmjmofii (oiieupezts ) | - | 01 Apr 2023 | |||
aorqhnznkf(qmlrjevzpu) = epoaxhgbly glpmjmofii (oiieupezts ) | |||||||
Not Applicable | - | - | ncopeismhc(uycvuhhbqa) = 0.35 siropfswwx (nlbbkgzryf ) View more | - | 22 Sep 2022 | ||
Not Applicable | 90 | qbfkoidrqk(cahacltraa) = rkgistsdqe cvoyjkwgwi (lyuevjlklu, 0.58) View more | Positive | 08 Aug 2022 | |||
qbfkoidrqk(cahacltraa) = qkqznlsemu cvoyjkwgwi (lyuevjlklu, 0.85) View more |